13FGuru
Sign in with Google Sign in with Discord

NASDAQ · Health Care

ADMA BIOLOGICS INC ADMA

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.

Sources StockAnalysis company profile stockanalysis.com
Biotechnology: Biological Products (No Diagnostic Substances)

Company profile

Business mix

  • The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
  • It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S.
  • pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities.
  • The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within biotechnology?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 2 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE 11.73 FCF 5.84% Buyback -3.58%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Fundsmith Terry Smith 0.1% $14.9M 2026-03-31
Duquesne Family Office Stanley Druckenmiller 0.4% $13,926 2026-03-31

Recent trading changes over the last 1 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 1 Last 1 13F filing periods
Net reducers 2 Last 1 13F filing periods
Unchanged holders 0 Share count unchanged
Increase amount $11,654 Estimated from net added shares
Reduction amount $211.6M Estimated from net reduced shares
Net share change / base shares -76.7% -10,534,151 / 13,729,254
Fundsmith Terry Smith 1 filing periods
13F 2026-03-31 Filed 2026-05-15
Major reduction Shares -21.5% 13F value change -$23.5M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 2,102,054 Last 1 periods -452,561 (-21.5%) Total shares 1,649,493 Value $14.9M
Duquesne Family Office Stanley Druckenmiller 1 filing periods
13F 2026-03-31 Filed 2026-05-15
Major increase Shares 512.9% 13F value change +$9,326
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 252,200 Last 1 periods +1,293,410 (+512.9%) Total shares 1,545,610 Value $13,926
Sachem Head Capital Management Scott Ferguson 1 filing periods
13F 2026-03-31 Filed 2026-05-15
Sold out Shares -100.0% 13F value change -$207.5M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 11,375,000 Last 1 periods -11,375,000 (-100.0%) Total shares 0 Value $0

Recent mentions

No public mentions.